Cargando…

Future Aspects of CDK5 in Prostate Cancer: From Pathogenesis to Therapeutic Implications

Cyclin-dependent kinase 5 (CDK5) is a unique member of the cyclin-dependent kinase family. CDK5 is activated by binding with its regulatory proteins, mainly p35, and its activation is essential in the development of the central nervous system (CNS) and neurodegeneration. Recently, it has been report...

Descripción completa

Detalles Bibliográficos
Autores principales: Oner, Muhammet, Lin, Eugene, Chen, Mei-Chih, Hsu, Fu-Ning, Shazzad Hossain Prince, G M, Chiu, Kun-Yuan, Teng, Chieh-Lin Jerry, Yang, Tsung-Ying, Wang, Hsin-Yi, Yue, Chia-Herng, Yu, Ching-Han, Lai, Chih-Ho, Hsieh, Jer-Tsong, Lin, Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720211/
https://www.ncbi.nlm.nih.gov/pubmed/31395805
http://dx.doi.org/10.3390/ijms20163881
_version_ 1783448072725987328
author Oner, Muhammet
Lin, Eugene
Chen, Mei-Chih
Hsu, Fu-Ning
Shazzad Hossain Prince, G M
Chiu, Kun-Yuan
Teng, Chieh-Lin Jerry
Yang, Tsung-Ying
Wang, Hsin-Yi
Yue, Chia-Herng
Yu, Ching-Han
Lai, Chih-Ho
Hsieh, Jer-Tsong
Lin, Ho
author_facet Oner, Muhammet
Lin, Eugene
Chen, Mei-Chih
Hsu, Fu-Ning
Shazzad Hossain Prince, G M
Chiu, Kun-Yuan
Teng, Chieh-Lin Jerry
Yang, Tsung-Ying
Wang, Hsin-Yi
Yue, Chia-Herng
Yu, Ching-Han
Lai, Chih-Ho
Hsieh, Jer-Tsong
Lin, Ho
author_sort Oner, Muhammet
collection PubMed
description Cyclin-dependent kinase 5 (CDK5) is a unique member of the cyclin-dependent kinase family. CDK5 is activated by binding with its regulatory proteins, mainly p35, and its activation is essential in the development of the central nervous system (CNS) and neurodegeneration. Recently, it has been reported that CDK5 plays important roles in regulating various biological and pathological processes, including cancer progression. Concerning prostate cancer, the androgen receptor (AR) is majorly involved in tumorigenesis, while CDK5 can phosphorylate AR and promotes the proliferation of prostate cancer cells. Clinical evidence has also shown that the level of CDK5 is associated with the progression of prostate cancer. Interestingly, inhibition of CDK5 prevents prostate cancer cell growth, while drug-triggered CDK5 hyperactivation leads to apoptosis. The blocking of CDK5 activity by its small interfering RNAs (siRNA) or Roscovitine, a pan-CDK inhibitor, reduces the cellular AR protein level and triggers the death of prostate cancer cells. Thus, CDK5 plays a crucial role in the growth of prostate cancer cells, and AR regulation is one of the important pathways. In this review paper, we summarize the significant studies on CDK5-mediated regulation of prostate cancer cells. We propose that the CDK5–p35 complex might be an outstanding candidate as a diagnostic marker and potential target for prostate cancer treatment in the near future.
format Online
Article
Text
id pubmed-6720211
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67202112019-10-30 Future Aspects of CDK5 in Prostate Cancer: From Pathogenesis to Therapeutic Implications Oner, Muhammet Lin, Eugene Chen, Mei-Chih Hsu, Fu-Ning Shazzad Hossain Prince, G M Chiu, Kun-Yuan Teng, Chieh-Lin Jerry Yang, Tsung-Ying Wang, Hsin-Yi Yue, Chia-Herng Yu, Ching-Han Lai, Chih-Ho Hsieh, Jer-Tsong Lin, Ho Int J Mol Sci Review Cyclin-dependent kinase 5 (CDK5) is a unique member of the cyclin-dependent kinase family. CDK5 is activated by binding with its regulatory proteins, mainly p35, and its activation is essential in the development of the central nervous system (CNS) and neurodegeneration. Recently, it has been reported that CDK5 plays important roles in regulating various biological and pathological processes, including cancer progression. Concerning prostate cancer, the androgen receptor (AR) is majorly involved in tumorigenesis, while CDK5 can phosphorylate AR and promotes the proliferation of prostate cancer cells. Clinical evidence has also shown that the level of CDK5 is associated with the progression of prostate cancer. Interestingly, inhibition of CDK5 prevents prostate cancer cell growth, while drug-triggered CDK5 hyperactivation leads to apoptosis. The blocking of CDK5 activity by its small interfering RNAs (siRNA) or Roscovitine, a pan-CDK inhibitor, reduces the cellular AR protein level and triggers the death of prostate cancer cells. Thus, CDK5 plays a crucial role in the growth of prostate cancer cells, and AR regulation is one of the important pathways. In this review paper, we summarize the significant studies on CDK5-mediated regulation of prostate cancer cells. We propose that the CDK5–p35 complex might be an outstanding candidate as a diagnostic marker and potential target for prostate cancer treatment in the near future. MDPI 2019-08-09 /pmc/articles/PMC6720211/ /pubmed/31395805 http://dx.doi.org/10.3390/ijms20163881 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Oner, Muhammet
Lin, Eugene
Chen, Mei-Chih
Hsu, Fu-Ning
Shazzad Hossain Prince, G M
Chiu, Kun-Yuan
Teng, Chieh-Lin Jerry
Yang, Tsung-Ying
Wang, Hsin-Yi
Yue, Chia-Herng
Yu, Ching-Han
Lai, Chih-Ho
Hsieh, Jer-Tsong
Lin, Ho
Future Aspects of CDK5 in Prostate Cancer: From Pathogenesis to Therapeutic Implications
title Future Aspects of CDK5 in Prostate Cancer: From Pathogenesis to Therapeutic Implications
title_full Future Aspects of CDK5 in Prostate Cancer: From Pathogenesis to Therapeutic Implications
title_fullStr Future Aspects of CDK5 in Prostate Cancer: From Pathogenesis to Therapeutic Implications
title_full_unstemmed Future Aspects of CDK5 in Prostate Cancer: From Pathogenesis to Therapeutic Implications
title_short Future Aspects of CDK5 in Prostate Cancer: From Pathogenesis to Therapeutic Implications
title_sort future aspects of cdk5 in prostate cancer: from pathogenesis to therapeutic implications
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720211/
https://www.ncbi.nlm.nih.gov/pubmed/31395805
http://dx.doi.org/10.3390/ijms20163881
work_keys_str_mv AT onermuhammet futureaspectsofcdk5inprostatecancerfrompathogenesistotherapeuticimplications
AT lineugene futureaspectsofcdk5inprostatecancerfrompathogenesistotherapeuticimplications
AT chenmeichih futureaspectsofcdk5inprostatecancerfrompathogenesistotherapeuticimplications
AT hsufuning futureaspectsofcdk5inprostatecancerfrompathogenesistotherapeuticimplications
AT shazzadhossainprincegm futureaspectsofcdk5inprostatecancerfrompathogenesistotherapeuticimplications
AT chiukunyuan futureaspectsofcdk5inprostatecancerfrompathogenesistotherapeuticimplications
AT tengchiehlinjerry futureaspectsofcdk5inprostatecancerfrompathogenesistotherapeuticimplications
AT yangtsungying futureaspectsofcdk5inprostatecancerfrompathogenesistotherapeuticimplications
AT wanghsinyi futureaspectsofcdk5inprostatecancerfrompathogenesistotherapeuticimplications
AT yuechiaherng futureaspectsofcdk5inprostatecancerfrompathogenesistotherapeuticimplications
AT yuchinghan futureaspectsofcdk5inprostatecancerfrompathogenesistotherapeuticimplications
AT laichihho futureaspectsofcdk5inprostatecancerfrompathogenesistotherapeuticimplications
AT hsiehjertsong futureaspectsofcdk5inprostatecancerfrompathogenesistotherapeuticimplications
AT linho futureaspectsofcdk5inprostatecancerfrompathogenesistotherapeuticimplications